Phathom Pharmaceuticals has crossed into operating profitability on a cash-expense basis one quarter earlier than its own plan, and that is the event the market is still struggling to price. The Florham Park gastrointestinal company spent a year shrinking a broad primary-care launch into a gastroenterologist-first sales model, and the second quarter is the first clean print of that pivot. Revenue nearly doubled while cash operating expense fell by about a third. The equity still sits near a fifty-two-week low because management also narrowed full-year revenue guidance, blaming prior-authorization friction rather than demand.
The tension is access, not science. Covered VOQUEZNA prescriptions still grew faster than cash-pay volume, yet physicians who already navigate the paperwork for their most severe reflux patients hesitate to repeat that work for milder cases. That hesitation is why the company trimmed the top of its revenue range even as it posted the first quarter of positive operating cash. Cash ended mid-year at $182 million. A Hercules term loan of $175 million still sits beside a much larger revenue-interest liability, so the operating-profit milestone is real and still thin.
The next several quarters decide whether the GI-first model compounds or whether payer friction caps the franchise below the blockbuster path management still describes. Eosinophilic esophagitis data and the start of an as-needed dosing trial both sit in the fourth quarter. Updated full-year revenue now sits in a mid-three-hundred-million band. Does sequential covered-prescription growth re-accelerate once office staff learn the prior-authorization cycle, or does the guidance cut mark a ceiling?